Regenxbio Inc
RGNX10.330USD
+0.070+0.68%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
522.89M시가총액
손실P/E TTM
자세한 내용은 Regenxbio Inc 회사
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc 정보
종목 코드 RGNX
회사 이름Regenxbio Inc
상장일Sep 17, 2015
CEOSimpson (Curran M)
직원 수353
유형Ordinary Share
회계 연도 종료Sep 17
주소9804 Medical Center Drive
도시ROCKVILLE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호20850
전화12405528181
웹사이트https://regenxbio.com/
종목 코드 RGNX
상장일Sep 17, 2015
CEOSimpson (Curran M)
Regenxbio Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+7768.00%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Wed, Jan 14
마지막 업데이트: Wed, Jan 14
주주
주주 유형
주주
주주
비율
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
기타
64.96%
주주
주주
비율
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
기타
64.96%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
33.70%
Investment Advisor
31.87%
Research Firm
9.14%
Hedge Fund
8.86%
Individual Investor
8.29%
Private Equity
0.50%
Family Office
0.31%
Bank and Trust
0.25%
Pension Fund
0.11%
기타
6.96%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
409
42.96M
84.86%
-6.45M
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Redmile Group, LLC
4.69M
9.27%
-82.33K
-1.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.16M
8.21%
-109.09K
-2.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.34M
6.59%
-83.09K
-2.43%
Sep 30, 2025
Fox (Allan Mark)
2.90M
5.73%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.61M
5.16%
-375.24K
-12.57%
Sep 30, 2025
State Street Investment Management (US)
1.98M
3.92%
+141.23K
+7.66%
Sep 30, 2025
Goldman Sachs & Company, Inc.
1.62M
3.2%
+15.37K
+0.96%
Sep 30, 2025
BlackRock Financial Management, Inc.
1.50M
2.97%
-226.30K
-13.07%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.45M
2.85%
+700.19K
+94.00%
Sep 30, 2025
AQR Capital Management, LLC
1.29M
2.55%
+359.46K
+38.64%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
WisdomTree BioRevolution Fund
2.25%
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Global X Genomics & Biotechnology ETF
0.65%
JPMorgan Fundamental Data Science Small Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.08%
더 보기
WisdomTree BioRevolution Fund
비율2.25%
iShares Neuroscience and Healthcare ETF
비율1.02%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.85%
Global X Genomics & Biotechnology ETF
비율0.65%
JPMorgan Fundamental Data Science Small Core ETF
비율0.45%
ALPS Medical Breakthroughs ETF
비율0.27%
State Street SPDR S&P Biotech ETF
비율0.24%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.13%
Fidelity Enhanced Small Cap ETF
비율0.12%
ProShares Ultra Nasdaq Biotechnology
비율0.08%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
